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Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in
low- and middle-income countries (LMICs). However, a gulf between paying markets and the endemicity of such
diseases has contributed to the dearth of R&D in meeting these public health needs. While the pharmaceutical
industry views emerging economies as potential new markets, most of the world’s poorest bottom billion now
reside in middle-income countries–a fact that has complicated tiered access arrangements. However, product
development partnerships–particularly those involving academic institutions and small firms–find commercial
opportunities in pursuing even neglected diseases; and a growing pharmaceutical sector in BRICS countries offers
hope for an indigenous base of innovation. Such innovation will be shaped by 1) access to building blocks of
knowledge; 2) strategic use of intellectual property and innovative financing to meet public health goals;
3) collaborative norms of open innovation; and 4) alternative business models, some with a double bottom line.
Facing such resource constraints, LMICs are poised to develop a new, more resource-effective model of innovation
that holds exciting promise in meeting the needs of global health.
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Infectious diseases remain a significant contributor to the
burden of disease in low- and middle-income countries
(LMICs). Leading communicable diseases from AIDS, tu-
berculosis and malaria to diarrheal diseases, measles, and
lower respiratory infections claim upwards of eleven mil-
lion lives in these countries each year [1]. The burden falls
disproportionately not only on some countries, but also
on vulnerable parts of the population. Notably, 95 percent
of deaths from respiratory infections and 98 percent of
deaths from diarrheal diseases occur in LMICs [2]; and
diarrhea, pneumonia, measles, and malaria take many
lives of children under five. Similarly, infectious diseases* Correspondence: anthony.so@duke.edu
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reproduction in any medium, provided the orlike schistosomiasis, hookworm and malaria contribute to
anemia, worsening outcomes both of mother and child in
pregnancy, while syphilis also adversely affects neonatal
mortality. As for diseases that make up substantial por-
tions of global disease burden–HIV/AIDS, tuberculosis
and malaria—over 95 percent of the deaths caused by each
of these diseases are also in LMICs. The toll of infectious
diseases comes in mortality and morbidity, lost work
productivity and economic losses, and the drag effect on
those trapped or tipped into poverty by illness.
The attainment of the Millennium Development Goals
(MDGs) is closely entwined with progress in reducing the
burden of infectious diseases. MDG 6 focuses on combat-
ing HIV/AIDS, malaria and other diseases while steps to-
wards meeting MDG 4 (reducing child mortality), MDG 5
(improving maternal health) and MDG 7C (improving
basic sanitation and sustainable access to safe drinking
water) also relate to the treatment of infectious diseases
[3]. MDG 8E (providing access to affordable essential
drugs in developing countries in cooperation with
pharmaceutical companies) and MDG 8F (making avail-
able benefits of new technologies, especially informationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tor) not only align with these goals, but also suggest in-
strumental means for accomplishing them [4].
From triple therapy for AIDS and directly-observed
therapy for TB to oral rehydration salts and vaccines for
childhood killers like diarrhea and pneumonia, the past
decade has witnessed significant advances. Between 2000
and 2010, 45 global health technologies were introduced
for use in resource-limited settings, and the current
R&D pipeline for global health includes 365 medical
products at various stages of development [5]. Neverthe-
less, the unfinished agenda will require further technol-
ogy innovation. Health technologies diagnose, prevent
and treat disease; reduce the risk of disease such as
through improved sanitation; mitigate health outcomes
(for example, by combating malnutrition); and ensure
better delivery of these interventions.
Still many of these technologies remain out of reach to
millions who might benefit. For LMICs as a group, the
annual health expenditure per capita is just under US
$200 as of 2010 [6]. While middle-income countries to-
gether have seen a substantial rise in per capita annual
health expenditure--from around US$50 in 1995 to
about US$220 in 2010--health spending for households
in low-income countries, overall, has remained much
lower, climbing just US$16 over the same period to US
$26 per capita. Though the price of antiretroviral (ARV)
therapy has fallen dramatically by 99 percent over the
past decade [7], less than a quarter of those in need of
ARVs actually received treatment in 2010 [8]. This leaves
at least 29.5 million people living with HlV residing in
low- and middle-income countries still without treat-
ment, based on 2009 prevalence data [9,10]. Such tech-
nologies can also come at considerable cost to these
health systems. Out-of-pocket payments remain the pri-
mary source for covering the cost of medicines in low-
and middle-income countries [11].
Applying a systems thinking perspective, more might be
done to reshape the enabling environment for innovating
such health technologies. Meeting these twin goals of
innovation and access is key to bringing technologies from
bench to bedside. Focusing on the pharmaceutical value
chain might offer insights on how best to ensure technol-
ogy innovation and access appropriate to disease-endemic
countries. Delivering effective artemisinin combination
therapy for malaria provides a case example where several
interventions along the value chain shape the availability
and affordability of this treatment.
Delivering Existing Health Technologies to Those in
Need--Artemisinin Combination Therapy for Malaria
The Affordable Medicines Facility-Malaria (AMFm)
has sought to stem irrational treatment approaches to
malaria. AMFm worked to negotiate for lower prices ofartemisinin combination treatment (ACT) with
manufacturers, subsidize the purchase of ACTs
through copayments, and support interventions that
encourage rational use of ACTs. By sharply reducing
the retail prices of ACTs, the initiative hoped to
displace oral artemisinin monotherapies and other
medicines, such as chloroquine and sulfadoxine-
pyrimethamine, to which resistance had emerged.
UNITAID, the Gates Foundation and DFID supported
the piloting of this intervention with US$216 million
while the Global Fund complemented this, committing
up to US$127 million towards supporting
interventions for scaling up ACT use effectively [12].
The premise and preliminary findings behind this pilot
illustrate the complexity of delivering even existing
innovations to those in need. Early findings from the
Health Action International pricing survey in six
African countries showed that the AMFm price bested
the originator brand and the lowest-priced generic,
approaching but not yet consistently beating the prices
of irrational alternatives, like chloroquine and
sulfadoxine-pyrimethamine [13]. In less than a year
though, six out of eight pilot countries met or exceeded
benchmarks for availability, price and market share of
quality-assured ACTs, both in rural and urban areas
[14]. Efforts in Tanzania showed that accredited drug
dispensing outlets could complement these upstream
interventions by increasing access to and dispensing of
subsidized artemisinin combination therapy [15].
However, the volatility in artemisinin supply upstream
has caused significant price fluctuations in the pricing
of the active pharmaceutical ingredient of this drug.
Though it may not offset entirely the greater demand
for artemisinin from an expanded AMFm, the
anticipated advent of artemisinin, sourced from
microbial production, by late 2012 is a technology that
may help stabilize and secure the supply of this
critical drug for ACT [16].
Innovation can take several forms. For disease-endemic
countries, the technology challenge may not only be one
of novel invention, but also local adaptation of an existing
technology. Such adaptation might be to target locally en-
demic strains, as for meningococcal or pneumococcal
vaccines, where the introduction of such technologies in
LMICs has lagged. Or such health technologies might re-
quire being lyophilized, kept in cold chain storage, or per-
haps soon stabilized in silk films [17] for transport in
tropical climates. Or perhaps crucially, technology adapta-
tion to meet the resource constraints in disease-endemic
countries--where trained health personnel or health care
infrastructure may be wanting--might be required.
Of course, encouraging innovation for disease-endemic
countries is not necessarily the same as engaging disease-
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technologies for their settings. Looking at industry-
supported phase 3 clinical trials conducted by the twenty
largest U.S.-based pharmaceutical companies, a third of
such studies are now being conducted solely outside of the
United States, and a majority of study sites now reside out-
side of the United States [18]. Much of this globalization
of clinical research is to low- and middle-income coun-
tries. Shifting that involvement upstream--from conduct-
ing clinical trials in disease-endemic settings to working
on the bench science--would also mark progress in build-
ing the innovation capacity of disease-endemic countries.
In considering access, several related dimensions--
each corresponding to a different part of the value chain
of delivering technologies–matter. The primary focus for
technology innovation is therapeutic access, which refers
to whether diagnostics, drugs or vaccines are under re-
search and development or not in the pipeline. Financial
and structural access issues also play important roles in
enabling diffusion of such technologies. The failure to
deliver existing technologies, like AIDS treatment or oral
rehydration salts for children with diarrhea, illustrates
the challenges of financial and structural access barriers,
respectively. Therapeutic access refers to how well the
R&D pipeline works, financial access to the market, and
structural access to the delivery system.
Discussion
Bridging the gulf between markets and disease
endemicity
By deaths and DALYs, the focus on HIV/AIDS, tubercu-
losis and malaria on the global health landscape is
understandable: the “Big Three” diseases account for
over 4.3 million deaths per year [19]. While the burden
of disease falls disproportionately still on low- and
middle-income countries, there remains a significant
paying market in industrialized countries as well.
Boosted by public funding for these diseases, private sec-
tor interest is also correspondingly greater.
In a survey of R&D projects focused on neglected dis-
eases, BioVentures for Global Health found 218 R&D
projects on AIDS, tuberculosis and malaria--over four
times the number of projects on diarrheal diseases (in-
cluding rotavirus, cholera, typhoid fever, shigellosis,
enterotoxigenic E. coli) and pneumococcal disease. By
contrast, these other diseases of poverty, specifically vari-
ous causes of diarrheal disease and pneumococcal infec-
tion, claim 3.8 million deaths each year [20]. The number
of projects cannot tell the full story: the state-of-the-art
and the technical feasibility of next steps vary by disease.
Still the difference should provoke reflection on how pri-
orities are set.
Traditional distinctions among Type I diseases (those
endemic in both North and South, but with a sizablepaying market in the North) and Type II diseases (also en-
demic globally, but disproportionately so in developing
countries, such as AIDS and tuberculosis) and Type III
diseases (endemic only in developing countries) depend
on the size of potential paying markets for these diseases.
Such distinctions may help bound likely contributions and
interest from the private sector in these areas of pharma-
ceutical discovery and R&D. Where there are no paying
markets, market failures result.
Bridging this gulf, public sector investments can play an
important role in driving this innovation. Between 2007
and 2010, the G-Finder survey found that 97 percent of
the research funding backing neglected disease research
projects originates from high-income countries [21].
Nearly 64 percent of all funders’ monies comes from the
United States. Most publicly funded product development
partnerships concentrate their missions around a unifying
disease and technology focus, but alternative approaches
spanning a cluster of diseases raise the prospect of sharing
a common technology platform.
As a market, emerging economies have caught the atten-
tion of the global pharmaceutical industry. On the one
hand, the industry eyes the growing middle and upper
classes of these emerging economies as potential paying
customers. On the other hand, 960 million of the bottom
billion in the world live in middle-income countries. This is
in sharp contrast to two decades ago when over 90 percent
of the poorest of the poor lived in low-income countries.
Most of these poor people live in countries such as India,
Pakistan, Indonesia, and Nigeria, which have graduated
from low- to middle-income status [22].
This has implications for pharmaceutical innovation
and access. For example, in establishing tiering
schemes that give preferential access, from licensed
technology to product prices, this tension has made
firms reluctant to offer such breaks to middle-income
countries. This is reflected in the challenges that the
Medicines Patent Pool faces in recruiting companies
to license voluntarily their HIV/AIDS drugs for gen-
eric production as part of fixed-dose combinations.
Similarly, the anchoring of the GlaxoSmithKline-
initiated Pool for Open Innovation Against Tropical
Neglected Diseases and WIPO Re:Search Consortium-
-both efforts to pool building blocks of knowledge
and to license them royalty-free to those working on
neglected diseases--places limits on geographic cover-
age to only least developed countries as a starting
condition.
This underscores the different circumstances facing
emerging economies and other developing countries.
The stark reality is that less than a quarter of all bio-
medical research publications and less than a third of
all clinical trials in Africa even relate to diseases that
comprise nearly 50 percent of the burden of disease
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both the research institutions most productive in pub-
lishing journal articles and filing patents were concen-
trated in a few countries in Africa (notably South
Africa, Nigeria and Egypt). Examining patterns of col-
laboration on biomedical publications, over three-
quarters of these journal articles were co-authored
with collaborators, but only 5.4 percent engaged insti-
tutions in more than one African country while the
preponderant majority of articles involved collabora-
tors in Europe or the United States. This pattern of
collaboration, in part, motivated the formation of the
African Network for Drugs and Diagnostics
Innovation, with its focus on intra-African coordin-
ation and collaboration on R&D.
Opportunity of technology innovation under resource-
constrained settings
Mobilizing public and private sector resources, product
development partnerships (PDPs) have stepped in to ad-
dress the market’s failure to bring forward treatments
for neglected diseases. A study of 63 neglected disease
projects at the end of 2004 tells an interesting story [24].
Half of these projects were conducted by multinational
firms, invariably on a “no profit-no loss” basis. Projects
from the other half were conducted on a commercial
basis by small-scale entities: small and medium enter-
prises, developing country firms and academic research
institutions. Arguably, these groups viewed the oppor-
tunity costs quite differently than did the multinational
corporations. This may be an important insight in tar-
geting incentives for companies to help overcome the
market’s failure.
A survey of product developers engaged in drug and
vaccine R&D for neglected diseases suggested, however,
that only 40 percent of such projects involved a PDP
[25], with the majority going forward without a PDP
partner. These included strong involvement of academic
institutions, particularly in the study of neglected trop-
ical diseases. Less than 3 percent of biotechnology com-
panies globally participate in neglected disease R&D, but
this still comes to more than 100 firms. Thirteen of the
twenty largest pharmaceutical companies are involved in
such projects. Multinational drug firms have also begun
to shift their patterns of R&D, with recent boosts in
approvals of new drugs targeting orphan diseases [26].
In some respects, orphan diseases and neglected diseases
may be two sides of the same coin. By value, both face
small markets: orphan diseases with small numbers of
patients, but treatments that may command high prices
in industrialized countries; neglected diseases with mil-
lions of patients, but hopes for very low cost treatments
per episode. Facing the looming cliff of patent expira-
tions, some of these firms might also be seeing theopportunity costs of smaller markets differently than in
the past.
Emerging economies may play an increasingly stra-
tegic role in this space. Already India and China are
making significant investments in domestic R&D efforts.
Among BRICS countries (Brazil, Russia, India, China,
and South Africa), foreign assistance to other develop-
ing countries has risen at near double-digit rates from
2005 to 2010 [27].
For Brazil, health has been a significant component of
the country’s foreign assistance budget. Brazil contribu-
ted approximately US$130 million to WHO and PAHO
between 2005 and 2009 [28] and pledged US$20 million
to the Global Alliance for Vaccines and Immunizations
over a twenty-year period [29]. Brazil also provided over
US$37 million to UNITAID between 2006 and 2011;
and in May 2011, Brazil enacted a law that donates US
$2 to UNITAID per international flight, a contribution
estimated to grow into a US$12 million commitment an-
nually [30]. Brazil has also initiated a public-private part-
nership to transfer ARV production technology to
Mozambique [31]. Together with the government of
Mozambique and the Vale Foundation (the philanthropic
arm of a Brazilian mining firm with operations in
Mozambique), Brazil’s Institute of Technology in Phar-
macos (Farmanguinhos) provided US$23 million to help
build an ARV manufacturing plant [32]. Once oper-
ational, the plant will produce five ARV drugs and other
pharmaceuticals, including a pain reliever and a drug for
high blood pressure. In another example of South-South
technology transfer, Farmanguinhos, with the Indian
drug manufacturer Cipla, also partnered with the Drugs
for Neglected Diseases Initiative (DNDi), a product de-
velopment partnership, to bring to market a new fixed-
dosed artemisinin-based combination treatment, ASMQ,
the first ACT with a three-year shelf life in tropical cli-
mates [33]. Farmanguinhos and Cipla agreed in 2008 to
manufacture and provide ASMQ to the public sector in
developing countries at cost (with a target price of US
$2.50 per full adult treatment).
Technology innovation in disease-endemic countries
Innovation for neglected diseases, more often than not,
is viewed less as an exemplar to emulate and more as an
exception. Just because pharmaceutical and biotechnol-
ogy firms contribute to neglected disease projects, some
might argue that this does not translate to new models
of R&D collaboration from which broader, more
generalizable lessons might be derived for more com-
mercially viable therapeutic areas.
The perception is, by value, that markets in LMICs are
considered small; and the diseases, are typically classified
as Type II or III. After all, over three-quarters of global
expenditures on pharmaceuticals are spent on 16
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countries [34]. However, the patent cliff faced by multi-
national pharmaceutical firms, the burden of non-
communicable diseases requiring treatment in low- and
middle-income countries, the availability of public sector
funding and philanthropic capital, and the growing foot-
print of indigenous innovation in the pharmaceutical
sector of emerging economies might prompt rethinking
this view.
Spurred initially by the struggle for affordable medicines
to treat HIV/AIDS, a decade-long policy process--
beginning with the WHO’s Commission on Intellectual
Property, Innovation and Public Health [35], continuing
with the World Health Assembly’s adoption of the Global
Strategy and Plan of Action on Public Health, Innovation
and Intellectual Property [36], and leading up to the
recently released recommendations of the WHO’s Con-
sultative Expert Working Group on Research and Develop-
ment: Financing and Coordination [37] —has sought to
reshape the way in which health technologies come to
market in resource-limited settings.
Several developments may shape and nurture the
direction this approach to innovation emerging from
developing countries takes. Important elements of this
enabling environment include 1) access to building
blocks of knowledge; 2) strategic use of intellectual
property and innovative financing to meet public health
goals; 3) collaborative norms of open innovation; and 4)
alternative business models, some with a double bottom
line.
Access to the building blocks of knowledge is key to
innovation and technology transfer. Journal subscription
costs pose barriers to accessing the latest developments
in research. In response, WHO has supported the Health
InterNetwork Access to Research Initiative (HINARI).
Working with publishers, HINARI provides tiered access
to journal articles for low- and middle-income countries.
This approach has been imperfect, with all BRICS coun-
tries, Indonesia, Thailand and other middle-income
countries ineligible for the discounted subscription
arrangements despite sizable poor populations and
under-resourced research institutions in these countries.
While such voluntary agreements provide work-around
solutions to improved access to the research literature,
industrialized countries have made significant strides
to advancing an open access model for sharing journal
publications. Departing from the traditional model of
subscription-supported publication, open access journals
raise revenues from other sources, ranging from endow-
ments and membership dues to advertising and upfront
submission or publication fees. As a result, published arti-
cles in open access journals are made available freely on-
line without subscription barriers. A growing number
of leading universities, from Harvard University to theMassachusetts Institute of Technology, have also estab-
lished institutional, open access repositories where faculty
may deposit their publications. Funders like the NIH and
the Wellcome Trust have taken steps to require grantees
to make available their journal publications in publicly ac-
cessible archives. The model of open access publication
not only may have more universal applicability, both
North and South, but also enables users to assemble rele-
vant publications from multiple journals, without the bar-
rier of subscription costs to each journal.
The past decade has witnessed shortfalls in the supply
of influenza vaccine to meet the H1N1 pandemic and
heightened concerns over the spread of emerging infec-
tious diseases like SARS and avian flu. Not wishing to be
last in queue for a vaccine or treatment, developing
countries have sought assurances from WHO’s Global
Influenza Surveillance and Response System (GISRS)
that the sharing of virus samples would result not just in
vaccines for industrialized countries, but also affordable
access for such technologies in their settings as well.
The Pandemic Influenza Preparedness Framework lays
out a standard material transfer agreement, a system for
benefit sharing and for contributions from pharmaceut-
ical manufacturers and public health researchers, and
hortatory measures encouraging Member States to urge
manufacturers to set aside vaccines for influenza strains
with pandemic potential for stockpiling and use by
developing countries, to engage in technology transfer
efforts, and to make such vaccines and antivirals avail-
able under tiered pricing arrangements [38]. Whether
these measures will suffice in the event of a pandemic
will surely be tested in the years ahead.
Anticipating the need to scale up this technology,
WHO has provided seed grants to 11 manufacturers in
low- and middle-income countries to establish or en-
hance their capacity to produce pandemic influenza vac-
cine. The Netherlands Vaccine Institute was not only
enlisted to provide training, but also to support an influ-
enza vaccine technology platform or hub to facilitate the
transfer of technology to these countries. Building upon
a “robust and transferable monovalent pilot process for
egg-based inactivated whole virus influenza A vaccine
production,” next steps are being planned for work
under this technology platform [39]. Such technology
platforms might be potentially developed for other diag-
nostic and therapeutic areas to accelerate innovation.
The strategic management of intellectual property rights
is central to securing access to these building blocks of
knowledge [40]. Even when publicly funded, patented
inventions may not be easily accessible by other researchers
or for use in disease-endemic countries. There may be even
less incentive to share when such inventions are proprietary
and privately funded. However, especially in the neglected
disease space, both tiering and pooling arrangements have
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ing, preferential discounts or even royalty-free access to re-
search inputs is provided, often bounded by field of use or
geography. For AIDS drugs and many vaccines, tiered pri-
cing arrangements offer price breaks to resource-limited
countries. Further upstream, many neglected disease pro-
jects benefit from tiered licensing arrangements, whereby
access to compounds otherwise inaccessible due to their
proprietary nature is provided. The R&D pathway for re-
purposing existing drugs can be shortened considerably
when such access is coupled with pre-clinical and even clin-
ical data on these compounds. Under pooling arrange-
ments, the transaction costs of bringing together needed
inputs for research are lowered and cross-licensing enabled.
With varying degrees of resulting access and other
forms of success, a patchwork of ad hoc tiering and
pooling arrangements have emerged. Both policy instru-
ments have their place in ensuring broader access to re-
search inputs. Collaborating with the Medicines for
Malaria Venture, GlaxoSmithKline’s release of the chem-
ical structures and assay data of over 10,000 compounds
with activity against the malaria parasite, Plasmodium
falciparum, is such an example. This deposit into the
pool of the European Bioinformatics Institute’s ChEMBL
database and the U.S. NIH PubChem database provides
wide access under a Creative Commons CC0 license
(work dedicated to the public domain with waiver of
copyright) [41]. Tiering and pooling often work in tan-
dem. The Medicines Patent Pool, the Pool for Open
Innovation Against Neglected Tropical Diseases, and the
WIPO Re:Search Consortium all represent pooling
arrangements, each with different tiered access condi-
tions on inputs into the pool. Some work by aggregating
research inputs upstream in the R&D pipeline, and
others recruit patented drugs downstream in the R&D
pipeline. For example, the Medicines Patent Pool’s mis-
sion is to secure voluntary licenses from pharmaceutical
companies of HIV/AIDS drugs that might be used in
new fixed-dose combinations or pediatric formulations.
In so doing, the generic licensing of such combinations
is meant to stir greater competition and thereby
innovation and affordability of such treatments. Negoti-
ating licenses, limited by field and geography, has proven
challenging. To date, the only license with a company
for AIDS medicines has been with Gilead. This license
restricts manufacturing to India, but extends access to
resulting products to a wider range of countries (though
still excluding several middle-income countries) than
under previous arrangements [42].
As with open access initiatives, funders can set norms
supportive of sharing knowledge and also lower the risks
of crossing the valley of death from pre-clinical to clin-
ical testing. The NIH recently launched the National
Center for Advancing Translational Sciences (NCATS).Created to “catalyze the generation of innovative meth-
ods and technologies” that might bring diagnostics and
therapeutics to first-in-human trials, NCATS provides a
spectrum of intramural and contracted services that en-
able small firms and academic research institutions to
secure needed preclinical support [43]. Funders can also
invest their philanthropic capital in ways to ensure more
affordable access in exchange for non-diluting cash for
biotechnology start-up companies. With Gates Founda-
tion support, the University of California, Berkeley
extended co-exclusive licenses for the microbial synthe-
sis of artemisinin--a key antimalarial drug--to Amyris
Biotechnologies and the Institute for One World Health
[44]. The University made the license royalty-free for
malaria indications in exchange for Amyris Biotechnolo-
gies’ commitment to produce artemisinin at no profit for
treating malaria in the developing world. Amyris, in re-
turn, also received substantial philanthropic capital sup-
port (US$12 million) from the Gates Foundation. This
enabled Amyris to develop proof of concept on its mi-
crobial synthesis process, which also has a dual market
application for synthesizing biofuels.
Establishing collaborative norms of open innovation
has deep roots in public sector funding of science.
The Wellcome Trust and the U.S. National Institutes
of Health (NIH) engaged leading centers involved in
the Human Genome Project to agree to the Bermuda
Rules, whereby investigators pledged to deposit gene
sequences of every 1000 base pairs within 24 hours of
completion into GenBank [45]. The intent was not
only to encourage sharing of data, but also to prevent
unnecessary patenting through defensive publishing.
NIH has also issued guidance to grantees for the
“timely release and sharing of final research data” for
others to use [46] and for minimizing unnecessary
encumbrances on the dissemination of publicly funded
research tools [47].
Increasingly, the pharmaceutical sector has recognized
the value of open innovation [48]. From Merck’s early
efforts to place expressed sequence tags into the public
domain to corporate participation in the Single Nucleo-
tide Polymorphisms Consortium, pharmaceutical firms
have understood the need to harness ideas from outside
their walls to fuel in-house R&D innovation. The poten-
tial application for open innovation is most evident for
emerging infectious diseases, where the patenting
process might be outpaced by the speed of a spreading
pandemic. The need for pooling patents on SARS to en-
able non-exclusive licensing anticipated the potential
problems of intellectual property holdings on developing
a diagnostic or treatment for the illness. However, the
SARS epidemic came and went before the patent pool
could be launched, highlighting the potential value of
open innovation norms for emerging diseases.
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open source innovation in biomedicine have also begun.
By contrast, open source innovation involves openness
and transparency with the goal of shared research col-
laboration, but also prevents third parties from acquiring
proprietary rights over what is generated by the commu-
nity. Notably, India’s Council for Scientific and Industrial
Research has embarked on the Open Source Drug Dis-
covery (OSDD) initiative, initially focused on TB drugs.
Using a web-based platform, hundreds of volunteers at a
network of universities, both in India and elsewhere,
have collaborated on re-annotating the Mycobacterium
tuberculosis genome. Their collective efforts made this
possible in just four months. Supported with govern-
ment funding, participants submit projects for open peer
review, contribute to on-line efforts under a system of
microattribution, and agree to sharing their work under
a click-wrap license. In not pursuing a conventional path
to drug discovery, OSDD hopes to “bring down the cost
of drug discovery significantly by knowledge sharing and
constructive collaboration” and “to discover new chem-
ical entities and to make them generic as soon as they
are discovered, thus expediting the process of drug dis-
covery” [49].
Summary
For many neglected diseases, the case for an alternative
business model is clear. On the demand side, the need
to provide affordable health technologies responsive to
public health needs and the local context of low- and
middle-income countries is urgent. On the supply side,
high volume, closer to marginal cost pricing might
match this need. Fortunately, there is growing capacity
among developing countries to respond. Developing
country vaccine manufacturers already supply 64 percent
of vaccines procured by UNICEF [50]; and more than 80
percent of annual purchase volumes of antiretroviral
drugs destined for low- and middle-income countries
come from Indian generic manufacturers [51].
Bridging the supply and demand side, there is need for a
more efficient model for R&D innovation. This will likely
require innovation of both products and processes.
Described by various names, the idea of jugaad innovation,
a Hindi word meaning “an innovative fix; an improvised so-
lution born from ingenuity and cleverness; resourceful”
captures, in part, the spirit of such efforts [52]. Others have
applied the descriptor, “frugal innovation” [53]. However, it
is important not to connote that such innovation will come
as a quick fix. Nor will it come out of a sense of thriftiness
alone, without a deeper understanding of the effective use
of resources. The enabling conditions for such innovation
must be carefully cultivated and nurtured, and this may re-
quire piloting new models for collaborative R&D efforts--
sharing resources, risks and rewards more effectively [54].Working under the constraints of a resource-limited en-
vironment, such innovation must be resource-effective, but
not substandard. This efficient use of resources is reflected
in the Innovation Efficiency Index scoring of countries like
China and India compared to developed countries. This
index compares outputs from innovation against the con-
straint of available inputs for innovation in a country, and
by this measure, China and India come out first and sec-
ond in the world [55]. Perhaps fittingly, some have sug-
gested that such innovation embraces Mahatma Gandhi’s
tenet of getting “more from less for more people,” [56] best
captured in his quote: “Earth provides enough to satisfy
every man’s need, but not every man’s greed” [57].
The enabling environment for resource-effective
innovation will likely accelerate not only health tech-
nologies for infectious diseases, but also for the growing
burden of non-communicable diseases. Technologies
like echocardiography have clinical value whether the
valvular heart disease traces to rheumatic fever, drugs or
atherosclerosis. The process of technology transfer, the
clinical trial platforms, and the training of scientists also
build towards the common purpose of bringing these
new health technologies from bench to bedside.
What is exciting for global health is that the world–
both North and South--has much to benefit from these
new approaches to innovation. Under increasing budget
constraints themselves, industrialized countries might
welcome cost-effective interventions born out of the
genius of innovation under resource constraint. Such
innovation might be potentially disruptive, in that a
product targeted at the base of the economic pyramid--
an initial market marginalized by competitors--might
migrate “up market” displacing established technologies
[58]. From point-of-care diagnostics to more affordable
drugs and vaccines, the necessity to bring more appro-
priate and affordable health technologies may indeed
spark a new approach to innovation.
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